BIOMAT Database Logo BIOMAT Database Logo

Temporal evolution of soluble Fas and Fas ligand in patients with orthotopic liver transplantation. 2008

Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Orient Organ Transplant Center, Tianjin First Central Hospital, Nankai District, Fukang Road, No. 24, 300192 Tianjin, PR China. wang_yu_l@yahoo.com.cn

OBJECTIVE The aim of this study was to analyze the expression levels of plasma soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with orthotopic liver transplantation (OLT) procedures routinely performed without venovenous bypass. METHODS The sFas and sFasL were analyzed in the blood of 20 consecutive patients who underwent transplantation. Blood samples were drawn from the radial artery at serial time points before, during, and after surgery. Plasma levels of sFas and sFasL were detected by Enzyme Linked-Immuno-Sorbent Assay. Plasma aspartate transaminase (AST) and alanine transaminase (ALT) were assayed by routine clinical chemistry testing. RESULTS Marked elevation of plasma AST and ALT were detected at the reperfusion and postoperation time points (P<0.001), with a peak on the first postoperative day. The mean plasma concentration of sFas and sFasL remained unchanged from preoperative to anhepatic phase (T1 to T3) (P> or =0.268). The sFas and sFasL concentrations were significantly higher at 15 and 60 min after reperfusion compared to the preoperative value (P< or =0.048). Postoperatively, sFas and sFasL concentration were decreased to preoperative levels on the first postoperative day (P> or =0.127). CONCLUSIONS The sFas and sFasL seem to be involved in reperfusion injury during OLT. The understanding of Fas may provide new insights into the mechanisms of ischemia/reperfusion injury during OLT.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D001219 Aspartate Aminotransferases Enzymes of the transferase class that catalyze the conversion of L-aspartate and 2-ketoglutarate to oxaloacetate and L-glutamate. EC 2.6.1.1. Aspartate Aminotransferase,Aspartate Transaminase,Glutamic-Oxaloacetic Transaminase,SGOT,Aspartate Apoaminotransferase,Glutamate-Aspartate Transaminase,L-Aspartate-2-Oxoglutarate Aminotransferase,Serum Glutamic-Oxaloacetic Transaminase,Aminotransferase, Aspartate,Aminotransferase, L-Aspartate-2-Oxoglutarate,Aminotransferases, Aspartate,Apoaminotransferase, Aspartate,Glutamate Aspartate Transaminase,Glutamic Oxaloacetic Transaminase,Glutamic-Oxaloacetic Transaminase, Serum,L Aspartate 2 Oxoglutarate Aminotransferase,Serum Glutamic Oxaloacetic Transaminase,Transaminase, Aspartate,Transaminase, Glutamate-Aspartate,Transaminase, Glutamic-Oxaloacetic,Transaminase, Serum Glutamic-Oxaloacetic
D015427 Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. Ischemia-Reperfusion Injury,Injury, Ischemia-Reperfusion,Injury, Reperfusion,Reperfusion Damage,Damage, Reperfusion,Injury, Ischemia Reperfusion,Ischemia Reperfusion Injury,Ischemia-Reperfusion Injuries,Reperfusion Damages,Reperfusion Injuries
D016031 Liver Transplantation The transference of a part of or an entire liver from one human or animal to another. Grafting, Liver,Hepatic Transplantation,Liver Transplant,Transplantation, Hepatic,Transplantation, Liver,Hepatic Transplantations,Liver Grafting,Liver Transplantations,Liver Transplants,Transplant, Liver
D053222 Fas Ligand Protein A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS. Antigens, CD178,CD178 Antigens,Tumor Necrosis Factor Ligand Superfamily Member 6,CD178 Antigen,CD95 Antigen Ligand,CD95 Ligand,CD95L,Fas Ligand,Fas Ligand (FasL),FasL Protein,TNF Superfamily, Member 6,Antigen, CD178

Related Publications

Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
[A study of soluble Fas and Fas ligand in patients with orthotopic liver transplantation].
February 2009, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Apoptosis and the expression of Fas and Fas-ligand antigen after orthotopic liver transplantation.
August 1998, Transplantation proceedings,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis.
October 2000, The British journal of ophthalmology,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
June 2001, Journal of critical care,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
December 2003, Burns : journal of the International Society for Burn Injuries,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease.
June 1998, Lancet (London, England),
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
December 2000, Respiratory medicine,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
September 2011, American journal of reproductive immunology (New York, N.Y. : 1989),
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
October 1998, Nephron,
Yuliang Wang, and Yawu Liu, and Ruifa Han, and Jie Yang, and Zhijun Zhu, and Yanyan Zhang, and Zhi Yao, and Wei Gao, and Zhongyang Shen
Circulating soluble Fas ligand in patients with gastric carcinoma.
December 2000, Cancer,
Copied contents to your clipboard!